Preoperative evaluation, clinical characteristics, and prognostic factors of nongenital metastatic ovarian tumors: review of 48 patients

Objective: To evaluate the clinicopathologic characteristics, methods for preoperative evaluation, prognostic factors, and overall survival of nongenital ovarian metastases (NGOM). Material and Methods: Forty-eight patients with NGOM followed between January 2001 and January 2009 in Cukurova University Department of Gynecologic Oncology were included in the study. Clinical characteristics including demographics, preoperative imaging methods, endoscopic evaluations, tumor markers, histopathologic findings, prognostic factors, types of surgery, modalities for adjuvant therapy and survival were analyzed. Results: The gastrointestinal tract is the most common location of the primary tumor; colonic origin was found in 41% of the patients (n = 20). All metastatic lesions were adenocarcinoma with 23% of these classified as Krukenberg and 29% as mucinous type adenocarcinoma. When the whole group was evaluated, median survival time was 15.7 months in patients and there were significant differences between the groups according to primary site. Histopathological subtypes and presence of peritoneal carcinomatosis affected the median survival. The significant prognostic factors were primary site and histopathologic subtypes of the NGOM. Conclusions: NGOM should be kept in mind to avoid inappropriate management and therapy in patients with surgically managed ovarian tumor, especially young patients with gastrointestinal complaints.

Nongenital ovarian metastases; Prognostic factors; Preoperative evaluation; Survival

[1] Young R.H., Scully R.E.: “Metastatic tumors of the ovary”. In: Kurman R.J. (ed.). Blaunsteins Pathology of the Female Genital Tract, 2002, 5th edition, New York, Springer.

[2] Mazur M.T., Hsueh S., Gersell D.J.: “Metastases to the female genital tract: analysis of 325 cases”. Cancer, 1984, 53, 1978.

[3] Moore R.G., Chung M., Granai C.O., Gajewski W., Steinhoff M.M.: “Incidence of metastasis to the ovaries from nongenital tract primary tumors”. Gynecol. Oncol., 2004, 93, 87.

[4] Ayhan A., Guvenal T., Salman M.C., Ozyuncu O., Sakinci M., Basaran M.: “The role of cytoreductive surgery in nongenital cancers metastatic to the ovaries”. Gynecol. Oncol., 2005, 98, 235.

[5] Kim W.Y., Kim T.J., Kim S.E., Lee J.W., Lee J.H., Kim B.G., Bae D.S.: “The role of cytoreductive surgery for non-genital tract metastatic tumors to the ovaries”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2010, 149, 97.

[6] Jiang R., Tang J., Cheng X., Zang R.Y.: “Surgical treatment for patients with different origins of Krukenberg tumors: outcomes and prognostic factors”. Eur. J. Surg. Oncol., 2009, 35, 92.

[7] Petru E., Pickel H., Heydarfadai M., Lahousen M., Haas J., Schaider H. et al.: “Nongenital cancers metastatic to the ovary”. Gynecol. Oncol., 1992, 44, 83.

[8] Brown D.L., Zou K.H., Tempany C.M., Frates M.C., Silverman S.G., McNeil B.J., Kurtz A.B.: “Primary versus secondary ovarian malignancy: imaging findings of adnexal masses in the radiology diagnostic oncology group study”. Radiology, 2001, 219, 213.

[9] Koyama T., Mikami Y., Saga T., Tamai K., Togashi K.: “Secondary ovarian tumors: spectrum of CT and MR features with pathologic correlation”. Abdom. Imaging, 2007, 32, 784.

[10] Skírnisdóttir I., Garmo H., Holmberg L.: “Non-genital tract metastases to the ovaries presented as ovarian tumors in Sweden 1990-2003: occurrence, origin and survival compared to ovarian cancer”. Gynecol. Oncol., 2007, 105, 166.

[11] de Waal Y.R., Thomas C.M., Oei A.L., Sweep F.C., Massuger L.F.: “Secondary ovarian malignancies: frequency, origin, and characteristics”. Int. J. Gynecol. Cancer, 2009, 19, 1160.

[12] Antila R., Jalkanen J., Heikinheimo O.: “Comparison of secondary and primary ovarian malignancies reveals differences in their pre- and perioperative characteristics”. Gynecol. Oncol., 2006, 101, 97.

[13] Fujiwara K., Ohishi Y., Koike H., Sawada S., Moriya T., Kohno I.: “Clinical implications of metastases to the ovary”. Gynecol. Oncol., 1995, 59, 124.

[14] Miller B.E., Pittman B., Wan J.Y., Fleming M.: “Colon cancer with metastasis to the ovary at time of initial diagnosis”. Gynecol. Oncol., 1997, 66, 368.

[15] Webb M.J., Decker D.G., Mussey E.: “Cancer metastatic to the ovary: factors influencing survival”. Obstet. Gynecol., 1975, 45, 391.

[16] Morrow M., Enker W.E.: “Late ovarian metastases in carcinoma of the colon and rectum”. Arch. Surg., 1984, 119, 1385.

[17] Rayson D., Bouttell E., Whiston F., Stitt L.: “Outcome after ovarian/adnexal metastectomy in metastatic colorectal carcinoma”. J. Surg. Oncol., 2000, 75, 186.

[18] Abu-Rustum N.R., Aghajanian C.A., Venkatraman E.S., Feroz F., Barakat R.R.: “Metastatic breast carcinoma to the abdomen and pelvis”. Gynecol. Oncol., 1997, 66, 41.

[19] Eitan R., Gemignani M.L., Venkatraman E.S., Barakat R.R., Abu-Rustum N.: “Breast cancer metastatic to abdomen and pelvis: role of surgical resection”. Gynecol. Oncol., 2003, 90, 397.

[20] Kim H.K., Heo D.S., Bang Y.J., Kim N.K.: “Prognostic factors of Krukenberg’s tumor”. Gynecol. Oncol., 2001, 82, 105.

[21] Cheong J.H., Hyung W.J., Chen J., Kim J., Choi S.H., Noh S.H.: “Survival benefit of metastasectomy for Krukenberg tumors from gastric cancer”. Gynecol. Oncol., 2004, 94, 477.